HUTCHMED (China) Ltd.
- HCM · Nasdaq
- Pharmaceutical Preparations
- Hong Kong, Hong Kong
- CIK 0001648257
Updated from SEC filings through
Top things to know
Executives
- Chig Fung Cheng Acting CEO and CFO Form 4, May 21, 2026
- Wei-guo Su CEO and CSO Form 4, May 21, 2026
- Lorenso Chiu Deputy Chief Financial Officer Form 4, May 21, 2026
- Charles George Rupert Nixon Group General Counsel Form 4, May 21, 2026
HUTCHMED (China) Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Hong Kong, Hong Kong. It trades as HCM on Nasdaq. Revenue was $549M in the fiscal year ending December 31, 2025, -13.0% from the year before.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $549M 20-F, 2026-03-05 | $630M 20-F, 2026-03-05 | $838M 20-F, 2026-03-05 | $426M 20-F, 2023-02-28 | $356M 20-F, 2023-02-28 |
| Operating income | -$39.2M 20-F, 2026-03-05 | -$43.7M 20-F, 2026-03-05 | $18.4M 20-F, 2026-03-05 | -$408M 20-F, 2025-03-19 | -$328M 20-F, 2024-02-28 |
| SG&A | $66.7M 20-F, 2026-03-05 | $64.3M 20-F, 2026-03-05 | $79.8M 20-F, 2026-03-05 | $92.2M 20-F, 2025-03-19 | $89.3M 20-F, 2024-02-28 |
| Net income | $457M 20-F, 2026-03-05 | $37.7M 20-F, 2026-03-05 | $101M 20-F, 2026-03-05 | -$361M 20-F, 2025-03-19 | -$195M 20-F, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Chig Fung Cheng | Acting CEO and CFO | Form 4, May 21, 2026 |
| Wei-guo Su | CEO and CSO | Form 4, May 21, 2026 |
| Lorenso Chiu Senior Vice President Finance - Business Development & Reporting | Deputy Chief Financial Officer | Form 4, May 21, 2026 |
| Charles George Rupert Nixon | Group General Counsel | Form 4, May 21, 2026 |
What HUTCHMED (China) Ltd does
We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 872.3 million (as of December 31, 2025) | 20-F, March 5, 2026 |
|---|---|---|
| Auditor | PricewaterhouseCoopers Zhong Tian LLP (Shenzhen, the People’s Republic of China) | Latest 10-K |
Recent 8-K events
No 8-K filings on file.
Frequently asked questions about HUTCHMED (China) Ltd
- What does HUTCHMED (China) Ltd do?
- In its own words, from Item 1 of its 10-K: "We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally."
- What is HUTCHMED (China) Ltd's revenue?
- $549M for the fiscal year ending December 31, 2025, from its 20-F filed March 5, 2026.
- Is HUTCHMED (China) Ltd profitable?
- HUTCHMED (China) Ltd reported net income of $457M for the fiscal year ending December 31, 2025.
- Who is the CFO of HUTCHMED (China) Ltd?
- Chig Fung Cheng, Acting CEO and CFO, as named in a 4 filed May 21, 2026.
- Where is HUTCHMED (China) Ltd headquartered?
- Hong Kong, Hong Kong.
- What is HUTCHMED (China) Ltd's stock ticker?
- HCM, HMDCF on Nasdaq.
- What industry is HUTCHMED (China) Ltd in?
- Pharmaceutical Preparations, SIC code 2834.
- Is HUTCHMED (China) Ltd a public company?
- Yes. HUTCHMED (China) Ltd files with the SEC under CIK 0001648257 and trades as HCM.
- Who audits HUTCHMED (China) Ltd?
- PricewaterhouseCoopers Zhong Tian LLP, Shenzhen, the People’s Republic of China, as named in its latest annual report (10-K).
- How many shares of HUTCHMED (China) Ltd are outstanding?
- 872.3 million shares as of December 31, 2025, from its 20-F filed March 5, 2026.